Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Interventions
FGF-1, Placebo
Drug
Lead sponsor
Venturis Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Topical Human FGF-1 for Wound Healing

NCT00916292
Conditions
Diabetic Foot Ulcers
Interventions
FGF-1 141
Drug
Lead sponsor
Phage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Wounds, Diabetes, Venous Stasis Ulcers
Interventions
FGF-1
Drug
Lead sponsor
Venturis Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warren, Pennsylvania
Conditions
Corneal Endothelial Dystrophy
Interventions
TTHX1114
Drug
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia • Washington, Missouri
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Conditions
Peripheral Arterial Occlusive Disease
Interventions
XRP0038 (NV1FGF)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota